# Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC

> **NCT06165900** · PHASE2 · RECRUITING · sponsor: **Shengjing Hospital** · enrollment: 136 (estimated)

## Conditions studied

- Stereotactic Radiotherapy
- Immunotherapy
- Breast Cancer

## Interventions

- **DRUG:** adebrelimab plus stereotactic radiotherapy followed by adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin)
- **DRUG:** adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin)

## Key facts

- **NCT ID:** NCT06165900
- **Lead sponsor:** Shengjing Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-26
- **Primary completion:** 2025-12-15
- **Final completion:** 2028-12-15
- **Target enrollment:** 136 (ESTIMATED)
- **Last updated:** 2024-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06165900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06165900, "Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT06165900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*